Trending...
- California: Governor Newsom announces appointments 9.10.25 - 357
- John Thomas calls for unity and prayer after tragic loss - 327
- Ayurveda, Ayurvedic medical Science and Ayurvedic Therapies, Dr.Abhay Kumar Pati - 320
SHANGHAI and SAN DIEGO, Nov. 7, 2024 ~ San Diego, California - WuXi XDC Cayman Inc. ("WuXi XDC"), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and other bioconjugates (XDCs), has been named the winner of the "Best CDMO" at the World ADC Awards 2024 for the second consecutive year. The company's consistent recognition at the World ADC Awards over the past three years, including being named the winner of "Best CDMO" in 2023 and "Best CMO Runner-up" in 2022, highlights its expertise and technical strength in driving innovation in the global ADC industry.
The prestigious award was presented at the World ADC San Diego conference, which brings together key industry experts, breakthrough technologies, and forward-thinking collaborations. The annual event recognizes outstanding achievements by teams, projects, technologies, and individuals in the global ADC industry. This year's conference highlighted the latest advancements in ADCs and XDCs from research through to commercialization.
Dr. Jimmy Li, CEO of WuXi XDC expressed his pride in winning this prestigious award for two consecutive years. He stated that it is a reflection of their team's relentless dedication to innovation and excellence. The recognition also underscores the significant trust their clients place in them as a global leader in the ADC industry.
More on The Californer
WuXi XDC's mission is to accelerate and transform the discovery, development, and manufacturing of bioconjugates through a comprehensive open-access platform. They aim to enable their global healthcare partners and benefit patients worldwide by providing state-of-the-art technologies and integrated solutions.
The company won the Best CDMO Winner award for its integrated one-stop CRDMO platform that significantly reduces timelines and mitigates risks associated with ADC development and manufacturing. With WuXi XDC's integrated solutions, they have shortened the DNA-to-IND timeline for ADCs to 15 months or less, cutting down the conventional timeline to enter clinical trials by almost half. Additionally, they accelerate the development to Biologics License Application (BLA) within 24-36 months.
WuXi XDC's success is attributed to their profound expertise in ADC technology, extensive experience in handling complex bioconjugates, and a truly integrated approach that unifies discovery, development, and manufacturing. By leveraging cutting-edge technologies and a global team of industry experts, WuXi XDC ensures seamless interdisciplinary collaboration, minimizing risks and maximizing efficiency throughout the ADC development process.
More on The Californer
Their all-in-one manufacturing strategy integrates all four key phases of ADC production - mAb intermediate, linker-payload, drug substance, drug product - into one single site. This approach ensures seamless coordination and the highest product quality, making WuXi XDC a reliable partner for clients seeking to advance their ADC/XDC programs efficiently and effectively. This combination of cutting-edge technology, industry experience, and integrated solutions distinguishes WuXi XDC as a leader in the evolving ADC landscape.
According to their 2024 interim report, WuXi XDC's leadership in the ADC field is demonstrated by its expanding client base of 419 clients globally. Notably, 13 of the top 20 global pharmaceutical companies (ranked by 2023 revenue) have chosen WuXi XDC as their trusted partner. This reflects the high level of confidence placed in the company's expertise and capabilities.
The recognition from the World ADC Awards highlights WuXi XDC's relentless pursuit of excellence in delivering comprehensive service solutions to global clients. As a leading CRDMO in ADC and bioconjugates, they strive to remain at the forefront of innovation and empower clients worldwide to accelerate the development of transformative therapies for patients worldwide.
The prestigious award was presented at the World ADC San Diego conference, which brings together key industry experts, breakthrough technologies, and forward-thinking collaborations. The annual event recognizes outstanding achievements by teams, projects, technologies, and individuals in the global ADC industry. This year's conference highlighted the latest advancements in ADCs and XDCs from research through to commercialization.
Dr. Jimmy Li, CEO of WuXi XDC expressed his pride in winning this prestigious award for two consecutive years. He stated that it is a reflection of their team's relentless dedication to innovation and excellence. The recognition also underscores the significant trust their clients place in them as a global leader in the ADC industry.
More on The Californer
- McKenzi Brooke Set to Electrify the Super Girl Surf Festival in Oceanside, California
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Ascend in Motion Expands Flat-Rate Transfers from LAX to San Diego
WuXi XDC's mission is to accelerate and transform the discovery, development, and manufacturing of bioconjugates through a comprehensive open-access platform. They aim to enable their global healthcare partners and benefit patients worldwide by providing state-of-the-art technologies and integrated solutions.
The company won the Best CDMO Winner award for its integrated one-stop CRDMO platform that significantly reduces timelines and mitigates risks associated with ADC development and manufacturing. With WuXi XDC's integrated solutions, they have shortened the DNA-to-IND timeline for ADCs to 15 months or less, cutting down the conventional timeline to enter clinical trials by almost half. Additionally, they accelerate the development to Biologics License Application (BLA) within 24-36 months.
WuXi XDC's success is attributed to their profound expertise in ADC technology, extensive experience in handling complex bioconjugates, and a truly integrated approach that unifies discovery, development, and manufacturing. By leveraging cutting-edge technologies and a global team of industry experts, WuXi XDC ensures seamless interdisciplinary collaboration, minimizing risks and maximizing efficiency throughout the ADC development process.
More on The Californer
- Cryptocurrency Quarterly Trading Volume Surpasses $15 Trillion Record High as BrazilNex Acknowledges Industry 'Growing Pains' Amid Market Speculation
- AHRFD Initiates Legal Proceedings Against Anwalt.de for Publishing Defamatory and False Content
- New Analysis Reveals the Complex Forces Driving the 'Great Human Reshuffle'
- AdamMoney Launches Nationwide Hiring for Remote Sales Representatives to Promote 1st of-Its-Kind Pr
- Elevate Unveils GroundComm X30 at 2025 International GSE Expo in Las Vegas
Their all-in-one manufacturing strategy integrates all four key phases of ADC production - mAb intermediate, linker-payload, drug substance, drug product - into one single site. This approach ensures seamless coordination and the highest product quality, making WuXi XDC a reliable partner for clients seeking to advance their ADC/XDC programs efficiently and effectively. This combination of cutting-edge technology, industry experience, and integrated solutions distinguishes WuXi XDC as a leader in the evolving ADC landscape.
According to their 2024 interim report, WuXi XDC's leadership in the ADC field is demonstrated by its expanding client base of 419 clients globally. Notably, 13 of the top 20 global pharmaceutical companies (ranked by 2023 revenue) have chosen WuXi XDC as their trusted partner. This reflects the high level of confidence placed in the company's expertise and capabilities.
The recognition from the World ADC Awards highlights WuXi XDC's relentless pursuit of excellence in delivering comprehensive service solutions to global clients. As a leading CRDMO in ADC and bioconjugates, they strive to remain at the forefront of innovation and empower clients worldwide to accelerate the development of transformative therapies for patients worldwide.
Filed Under: Business
0 Comments
Latest on The Californer
- WesternU researchers show Osteopathic Manipulative Treatment improves efficacy of COVID-19 vaccine
- Vesica Health Receives AUA Guideline Inclusion
- Steward's Plumbing Sponsors the 2025 Samson Challenge, Bringing Community, Fitness, and Fun Together in Albuquerque
- Machine Vision Products Unveils New Homepage at Visionpro.com
- Global biotech leaders Amgen and Gilead announcing expansions in California, the #1 state for life sciences
- California: Governor Newsom proclaims Latino Heritage Month
- MEDIA ALERT: Cisco's WebexOne Event Spotlights Global AI Brands and Ryan Reynolds, Acclaimed Actor, Film Producer, and Entrepreneur
- Patrick Perez Steps Beyond Crunchyroll to Shape the Next Wave of Streaming & Media Innovation
- Mesa West Capital Originates $43.5 Million Loan to Refi LA Area Apartment Community
- 10xLaw.com Extends Employment Opportunity to Kim Kardashian
- DecisionPoint Technologies Accelerates Growth with Acquisition of Acuity Technologies
- CCHR: Involuntary Commitment Is Eugenics Repackaged as "Mental Health Care"
- Pacsun Announces Industry First Pacsun Youth Advisory Council: Empowering Its Consumers as Co-Creators in Brand Strategy
- Q2 2025 Industry Impact Report Underscores Semiconductor Expansion, Talent Development and Sustainability Milestones
- 84 Ethiopian Churches Change Signboards to Shincheonji Church of Jesus
- BTXSGG Outlines Four-Pillar Framework to Enhance Digital Asset Security and Compliance
- NJTRX Positions for Next-Generation Asset Trading with U.S. Regulatory Framework
- America's SBDC Announces 2025-2026 Board of Directors
- Avoid Swirl Marks When You Get a Car Wash in Downey CA
- Freedom Flourishes in Dutch Capital on Destination: Scientology, Amsterdam